Publications by authors named "Faez Ahmed"
Aim: This study evaluated the efficacy, safety, and immunogenicity of biosimilar adalimumab drug Advixa® (Incepta Pharmaceuticals Ltd, Dhaka, Bangladesh) in patients with moderate to severe rheumatoid arthritis (RA) compared to the reference drug Humira® (AbbVie Inc., North Chicago, IL, USA).
Methods: In this randomized, double-blind, prospective, parallel-group, active-controlled, non-inferiority trial, each of 144 patients was treated with six doses of Advixa® biweekly for up to 12 weeks.
Meningococcal disease is caused by Neisseria meningitidis or meningococcus. Every year globally around 1.2 million people are affected and approximately 120,000 deaths occur due to meningitis.
View Article and Find Full Text PDFArticle Synopsis
- Bangladesh faces ongoing cholera epidemics, resulting in over 300,000 severe cases and 4,500 deaths annually, with inadequate oral cholera vaccines limiting control efforts.
- A public-private partnership led to the development and testing of a locally-produced Oral Cholera Vaccine (OCV) called Cholvax, compared to the internationally licensed Shanchol.
- A clinical trial involving 2,052 healthy participants showed that Cholvax was safe and had comparable immunogenicity to Shanchol, supporting its potential use to help reduce cholera in Bangladesh.
Worldwide Hepatitis B is known as one of the imperative causes of mortality and morbidity as well as occupational health hazard among health workers. Bangladesh is intermediate endemic country for Hepatitis B infection for which the government has introduced hepatitis B vaccination into the Expanded Programme on Immunization (EPI) nationwide since 2009 for new born children. However, the people who were born before 2009, was dependent on imported hepatitis B vaccine as there was no locally manufactured hepatitis B vaccine in Bangladesh.
View Article and Find Full Text PDF